- Home
- GANX vs VTVT Comparison
GANX vs VTVT Comparison
Compare GANX & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- VTVT
- Stock Information
- Founded
- GANX 2017
- VTVT 2015
- Country
- GANX United States
- VTVT United States
- Employees
- GANX N/A
- VTVT N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- GANX Health Care
- VTVT Health Care
- Exchange
- GANX Nasdaq
- VTVT Nasdaq
- Market Cap
- GANX 53.8M
- VTVT 56.7M
- IPO Year
- GANX 2021
- VTVT 2015
- Fundamental
- Price
- GANX $1.72
- VTVT $17.85
- Analyst Decision
- GANX Strong Buy
- VTVT Strong Buy
- Analyst Count
- GANX 5
- VTVT 2
- Target Price
- GANX $8.20
- VTVT $35.50
- AVG Volume (30 Days)
- GANX 299.5K
- VTVT 9.3K
- Earning Date
- GANX 08-07-2025
- VTVT 08-07-2025
- Dividend Yield
- GANX N/A
- VTVT N/A
- EPS Growth
- GANX N/A
- VTVT N/A
- EPS
- GANX N/A
- VTVT N/A
- Revenue
- GANX N/A
- VTVT $17,000.00
- Revenue This Year
- GANX N/A
- VTVT N/A
- Revenue Next Year
- GANX N/A
- VTVT N/A
- P/E Ratio
- GANX N/A
- VTVT N/A
- Revenue Growth
- GANX N/A
- VTVT N/A
- 52 Week Low
- GANX $0.89
- VTVT $12.12
- 52 Week High
- GANX $3.19
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- GANX 49.29
- VTVT 59.11
- Support Level
- GANX $1.55
- VTVT $14.83
- Resistance Level
- GANX $1.79
- VTVT $15.16
- Average True Range (ATR)
- GANX 0.16
- VTVT 0.77
- MACD
- GANX -0.00
- VTVT 0.33
- Stochastic Oscillator
- GANX 44.53
- VTVT 91.21
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.